Skip to main content

Table 2 Subgroup analysis for cardiac mortality: Nicorandil use

From: Decreased cardiac mortality with nicorandil in patients with ischemic heart failure

Factor Subgroup n HR 95% Cl P value Interaction P value
Total   334 0.512 0.275–0.953 0.035 -
Age ≥75 143 0.807 0.344–1.890 0.621 0.252
<75 191 0.380 0.153–0.942 0.037
Sex Male 255 0.449 0.216–0.932 0.032 0.403
Female 79 0.737 0.213–2.547 0.629
LVEF Reduced 244 0.623 0.325–1.192 0.153 0.405
Preserved 90 0.245 0.029–2.102 0.200
LMT Present 19 1.240 0.000–3.420 0.581 0.968
Absent 315 0.492 0.259–0.934 0.030
3VD Present 85 0.672 0.244–1.849 0.441 0.482
Absent 249 0.425 0.188–0.962 0.040
PCI Present 245 0.556 0.272–1.138 0.108 0.646
Absent 89 0.422 0.120–1.483 0.179
CABG Present 69 0.181 0.036–0.897 0.036 0.128
Absent 265 0.718 0.366–1.409 0.336
Diabetes Present 207 0.412 0.177–0.957 0.039 0.361
Absent 127 0.742 0.296–1.858 0.523
CKD Present 229 0.434 0.217–0.871 0.019 0.206
Absent 105 1.252 0.280–5.596 0.769
Dialysis Present 44 0.338 0.073–1.568 0.166 0.595
Absent 290 0.557 0.282–1.100 0.092
β-blockers Present 278 0.483 0.229–1.022 0.057 0.469
Absent 56 0.830 0.273–2.523 0.743
Statins Present 220 0.720 0.324–1.604 0.422 0.425
Absent 114 0.400 0.139–1.153 0.090
Anti-platelet agents Present 299 0.600 0.316–1.140 0.119 0.907
Absent 35 0.041 0.000–215.058 0.464
Nitrates Present 78 0.551 0.188–1.616 0.277 0.814
Absent 256 0.474 0.219–1.027 0.058
  1. LVEF left ventricular ejection fraction, LMT left main trunk, 3VD three-vessel disease, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, CKD chronic kidney disease